Basit öğe kaydını göster

dc.contributor.authorGökcü, Mehmet
dc.contributor.authorGüngördük, Kemal
dc.contributor.authorAşıcıoğlu, Osman
dc.contributor.authorÇetinkaya, Nilüfer
dc.contributor.authorGüngör, Tayfun
dc.contributor.authorPakay, Gonca
dc.contributor.authorKarateke, Ateş
dc.date.accessioned2020-11-20T15:01:58Z
dc.date.available2020-11-20T15:01:58Z
dc.date.issued2016
dc.identifier.issn1757-2215
dc.identifier.urihttps://doi.org/10.1186/s13048-016-0276-1
dc.identifier.urihttps://hdl.handle.net/20.500.12809/2324
dc.descriptionWOS: 000385879800002en_US
dc.descriptionPubMed ID: 27756415en_US
dc.description.abstractBackground: The optimal surgical management and staging of borderline ovarian tumors (BOTs) are controversial. Institutions have different surgical approaches for the treatment of BOTs. Here, we performed a retrospective review of clinical characteristics, surgical management and surgical outcomes, and sought to identify variables affecting disease-free survival (DFS) and overall survival (OS) in patients with BOTs. Methods: A retrospective review of ten gynecological oncology department databases in Turkey was conducted to identify patients diagnosed with BOTs. The effects of type of surgery, age, stage, surgical staging, complete versus incomplete staging, and adjuvant chemotherapy were examined on DFS and OS. Results: In total, 733 patients with BOTs were included in the analysis. Most of the staged cases were in stage IA (70.4 %). In total, 345 patients underwent conservative surgeries. Recurrence rates were similar between the conservative and radical surgery groups (10.5 % vs. 8.7 %). Furthermore we did not find any difference between DFS (HR = 0.96; 95 % confidence interval, CI = 0.7-1.2; p = 0.576) or OS (HR = 0.9; 95 % CI = 0.8-1.1; p = 0.328) between patients who underwent conservative versus radical surgeries. There was also no difference in DFS (HR = 0.74; 95 % CI = 0.8-1.1; p = 0.080) or OS (HR = 0.8; 95 % CI = 0.7-1.0; p = 0.091) between complete, incomplete, and unstaged patients. Furthermore, receiving adjuvant chemotherapy (CT) for tumor stage >= IC was not an independent prognostic factor for DFS or OS. Conclusions: Patients undergoing conservative surgery did not show higher recurrence rates; furthermore, survival time was not shortened. Detailed surgical staging, including lymph node sampling or dissection, appendectomy, and hysterectomy, were not beneficial in the surgical management oF BOTs.en_US
dc.item-language.isoengen_US
dc.publisherBiomed Central Ltden_US
dc.item-rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBorderline Ovarian Tumoren_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectSurgeryen_US
dc.titleBorderline ovarian tumors: clinical characteristics, management, and outcomes - a multicenter studyen_US
dc.item-typearticleen_US
dc.contributor.departmentMÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.contributor.authorID0000-0002-2325-1756
dc.contributor.institutionauthorGüngördük, Kemal
dc.identifier.doi10.1186/s13048-016-0276-1
dc.identifier.volume9en_US
dc.relation.journalJournal of Ovarian Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster